TIME FOR LIFE

RITUXIMAB

  • It is targeted therapy drug – chimeric monoclonal antibody to the lymphocyte’s transmembrane antigen CD20
  • R-Маb® is the first biosimilar of Mabtera®/Rituxan® (F. Hoffmann La Roche AG) in Belarus with the identity of the molecular structure and mechanisms of action, efficacy and safety profile proven in comparative clinical studies
  • Currently R-Mab® is approved to first-line treatment of B-cell non-Hodgkin’s lymphomas and chronic lymphocytic leukemia, rheumatoid arthritis and granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis